2016, Number 4
Disease activity assessment of rheumatoid arthritis in daily practice using the clinical disease activity index (CDAI)
Mercado U
Language: Spanish
References: 6
Page: 415-419
PDF size: 438.72 Kb.
ABSTRACT
Background: The clinical disease activity index (CDAI) with 28 joint counts measures the activity of rheumatoid arthritis (RA) without laboratory tests.Objetive: To evaluate the CDAI in daily practice in RA patients at one year of the symptoms onset.
Material and Method: A prospective study was done with 120 consecutive patients with early RA ≤ 12 months (101 women, 19 men) seen in the rheumatology consult within 1 year of symptoms onset. The CDAI was divided into four categories: high or severe activity ›22, moderate ›10-22, mild ‹10 and remission ≤2.8. Functional disability (HAQ, health assessment questionnaire, 0-3 score) was also evaluated. A combination of methotrexate and sulfasalazine or chloroquine and low-dose prednisone 2.5-5.0 mg/d was administered.
Results: At baseline, 88 (73%) patients had high activity and 32 (27%) had moderate-mild activity. At 6 months 3% had high activity, whereas 96 (80%) were in remission (median 0, range 0-2.6). At 12 months, 110 patients (91%) were in remission and 6 (5%) had mild activity. The median score of HAQ was 1.4 (range 0.5-3.0) and at 12 months was 0 (range 0-1.2) There was a good correlation between HAQ and CDAI.
Conclusion: The CDAI score is a clinical tool that omits laboratory tests. Remission, defined as a CDAI ≤2.8 was achieved so early as 6 months. This study also showed improvement in functional ability.
REFERENCES